MwanzoMOLN • NASDAQ
add
Molecular Partners AG
Bei iliyotangulia
$ 4.69
Bei za siku
$ 4.39 - $ 4.72
Bei za mwaka
$ 3.36 - $ 5.36
Thamani ya kampuni katika soko
179.32M USD
Wastani wa hisa zilizouzwa
elfu 3.42
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 4.48M | -16.15% |
Mapato halisi | -12.65M | -12.62% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.36 | -20.00% |
EBITDA | -12.44M | 14.47% |
Asilimia ya kodi ya mapato | -0.03% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 93.06M | -37.73% |
Jumla ya mali | 102.11M | -35.59% |
Jumla ya dhima | 21.77M | 28.90% |
Jumla ya hisa | 80.33M | — |
hisa zilizosalia | 37.41M | — |
Uwiano wa bei na thamani | 2.18 | — |
Faida inayotokana na mali | -29.56% | — |
Faida inayotokana mtaji | -34.98% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -12.65M | -12.62% |
Pesa kutokana na shughuli | -11.15M | 15.49% |
Pesa kutokana na uwekezaji | 11.95M | 365.95% |
Pesa kutokana na ufadhili | elfu -300.00 | -101.96% |
Mabadiliko halisi ya pesa taslimu | elfu 294.00 | 115.65% |
Mtiririko huru wa pesa | -6.65M | -4.92% |
Kuhusu
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
149
